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A b s t r a c t  
Poly (lactic-co-glycolic acid) nanoparticles loaded with Aripiprazole has been developed as a new 
therapeutic strategy to achieve its controlled release profile suitable for parenteral administration. 
Nanospheres composed of different lactic/glycolic acid ratios and drug compositions were 
synthesized and loaded with Aripiprazole by emulsion/solvent evaporation method and subsequently 
characterized by particle-size distribution, scanning electron microscopy, encapsulation efficiency 
and in?vitro drug release studies. Specific drug-polymer interactions are engineered by optimizing 
the lactide to glycolide ratio (L:G ratio) and including specific polymer hydrophobicity. 
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Introduction 
Drug delivery has been improved with the translation of several 
nanoscale drug delivery systems into the clinic, although the full 
potential of these systems is only now starting to be explored. 
Nanoscale drug delivery systems have shown the ability to 
encapsulate a variety of therapeutic agents, such as small 
molecules (hydrophilic and/or hydrophobic), peptide protein-based 
drugs, and nucleic acids. By encapsulating these molecules inside 
a nanocarrier, the solubility and stability of drugs can be improved, 
providing an opportunity to re-evaluate the therapeutic potential of 
drugs previously discounted because of poor pharmacokinetics [1].  
Biodegradable micro/nanoparticles are promising candidates for 
extended release of hydrophobic drugs. PLGA based 
microparticles have been studied extensively and several products 
are available on market [2, 3]. In recent years, biodegradable 
nanoparticles for controlled drug delivery became a valuable 
approach to overcome the potential serious side effects arising 
from lifelong, systematic administration of therapeutic agents [4, 5]. 
However for site specific controlled drug delivery, nanoparticles 
offer additional advantages due to their submicron size [6]. Due to 
its unique properties PLGA copolymers have been used in 
controlled delivery of many proteins, drugs and other factors, such 
as cytokines, harmones, enzymes and vaccines [7-11]. The 
controlled release of a model hydrophobic drug from PLGA 
nanoparticles depends on the characteristics of the particles, 
including particle size, size distribution, drug content, incorporation, 
and surface morphology [12]. The mechanism of drug release 
plays a vital role in determining how the above properties influence 
the in-vitro release behaviour. 
Aripiprazole is an antipsychotic drug and is used mainly in the 
management of mental illness and is also used in the treatment of 
various forms of epilepsy [13-15]. An uninterrupted supply of 
antipsychotic medication therapy is vital for patient health. A long 
term controlled drug delivery parenteral formulations could be an 
ideal candidate to solve all these problems. Such medication is 
very useful in overcoming the problem of patient noncompliance 
and minimizes the incidence and severity of adverse side effect as 
with oral tablet dosage form. Nanospheres are one nanoparticulate 
delivery system and are prepared to obtain prolonged or controlled 
drug delivery, to improve bioavailability or stability, and to target 
drug to specific sites. Nanoparticles can also offer advantages like 
limiting fluctuation within therapeutic range, reducing side effects, 
decreasing dosing frequency and improving patient compliance. 
The aim of this study was to prepare Aripiprazole loaded PLGA 
nanoparticles to achieve a controlled drug release profile suitable 
for parenteral administration. First some important formulation 
variables (polymer and drug ratio) were optimized to obtain 
spherical particles. Optimized formulations were further evaluated 
by surface properties, encapsulation efficiency, particle size 
distribution and Aripiprazole release rate. The influence of 
formulation variables on the nanosphere properties was examined 
and the nanosphere formulations suitable to achieve our goal were 
selected.  
Materials and Experimental Methods 
Materials  
Lactic acid, glycolic acid and poly (ethylene glycol) were supplied 
by Sigma Aldrich chemicals (St. Louis, USA). Aripiprazole drug 
was received as a gift sample from BAL pharma, Bangalore, India. 
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All chemicals were AnalaR grade and were used as received. 
Throughout the experiment double-distilled water was used.  
Preparation of Aripiprazole loaded PLGA nanoparticles 
Aripiprazole loaded PLGA nanoparticles with different LA:GA (lactic 
acid:glycolic acid) ratios (G50; G25; G15) were prepared by oil in 
water emulsion/solvent evaporation method. Aripiprazole and 0.5 g 
of PLGA was dissolved in 3 ml of methylene chloride 
(DCM)/acetone as a solvent. This mixture was added to a 2% PEG 
aqueous solution with stirring (12,000 rpm) to achieve an O/W 
emulsion system. Then, the emulsified system was stirred with a 
magnetic stirrer under reduced pressure to evaporate the DCM and 
form polymer nanoparticles. The nanospheres were then isolated 
by filtration through vacuum and washed 4-5 times with distilled 
water and dried at room temperature for 24 hours. 
Nanoparticle Characterization 
Dynamic light scattering 
The prepared nanoparticles were dispersed in a water solution, 
added to a cuvette and analyzed by dynamic light scattering (DLS, 
90 plus particle size analyser, Brookhaven instruments, USA), in 
order to obtain size and its disparsity. When the PDI values varied 
between 0.01 and 0.7, the particles would have narrow 
distributions. The high values of PDI (PDI>0.7) indicated very 
broad distributions [16]. Zeta potential was determined by 
sonicating the samples in 1 mL of distilled water, and then 
subjecting to dynamic light scattering. 
Scanning electron microscopy  
Scanning electron microscopy (SEM, jeol, USA, 5kV) was used to 
determine the size, shape and surface texture of the nanoparticles 
as well as to verify the results obtained with dynamic light 
scattering.  
Drug loading and encapsulation efficiency 
The Aripiprazole content and entrapment efficiency were measured 
using HPLC (water, USA) with a reversed phase symmetry C18 5.0 
micrometer column (4.6mm x 150 mm). The mobile phase used for 
the column was 38% acetonitrile and 62% 10 mM, pH 4.8 
ammonium acetate solution. After being passed through the MCX 
cartridge, a 1ml of nanoparticulate suspension was dissolved in 40 
ml of mobile phase and a 50 øl aliquot of this sample was injected 
in HPLC machine with an auto injector. The column effluent was 
detected at 254 nm by UV spectrophotometer. A calibration curve 
for Aripiprazole was obtained using series of Aripiprazole 
standards prepared in the mobile phase. The calibration curve was 
linear in the range of concentration measured. Actual drug loading 
and encapsulation efficiencies were calculated using the following 
equations. 
 
 
 
In-vitro release studies 
In vitro release studies were performed at 370 C using the Tablet 
dissolution tester (Disso test, Lab India, Mumbai, India) equipped 
with six paddles at a paddle speed of 100 rpm. About 50 mL of 
phosphate buffer solution (pH=7.4) was used as the dissolution 
media. The sample was sealed in a dialysis bag, which was 
suspended in a sealed beaker containing release medium at 
constant stirring. At a fixed time intervals, 2 mL of the resultant 
release medium was sampled for the analysis of Aripiprazole 
content, then 2 mL of the fresh release medium was immediately 
added to maintain the original volume. The amount of Aripiprazole 
released was analyzed based on the standard curve using a UV 
Spectrophotometer at the λmax of 246 nm. The cumulative amount 
of drug released into the media at each time point was evaluated 
as the percentage of total drug release to the initial amount of the 
drug. 
Results and Discussion 
Drug content and entrapment efficiency 
As the initial Aripiprazol concentration is increased, the drug 
content first increases, then plateaus and finally decreases as 
shown in Figure 1a, while the drug incorporation efficiency remains 
constant and then decreases as shown in Figure 1b. 
 
Figure 1a. Effect of initial Aripiprazole concentration on the drug 
content. 
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The drug content in the nanoparticles is affected by the drug-
polymer interaction and the drug miscibility in the polymer. The 
importance of drug miscibility in the polymer has been discussed 
[16] for a hydrophobic drug-polymer system of dexamethasone 
loaded PLGA/PLA nanoparticles. They have reported that higher 
drug-polymer miscibility leads to higher drug incorporation. In our 
results as the L:G ratio is increased from 50:50 to 85:15, the drug 
content and incorporation increases. This happens due to 
increased hydrophobicity of polymer at higher L;G ratios, which 
increases the hydrophobic interaction of Aripiprazole with PLGA.  
 
Figure 1b. Effect of initial Aripiprazole concentration on the drug 
incorporation efficiency. 
Particle size and size distribution 
To determine the effect of lactic:glycolic acid ratio on the PLGA 
polymer different weight ratios (50:50, 75:25 and 85:15) were used. 
Exactly the same preparation method was used for the three 
polymers and the results showed that the PLGA with a higher lactic 
amount gives a smaller size as well as a zeta potential value closer 
to zero. All nanosphere lots presented a consistent size distribution 
histogram and the encapsulation efficiency ranged from 20-40% 
(Table 1). It can also be observed that the presence of drug during 
the preparation of the nanoparticles, gives a smaller and less 
negative value of the zeta potential. 
 
Table 1. The effect of the lactic:glycolic acid ratio on the size, PDI, 
zeta potential and encapsulation efficiency  PLGA nanoparticles 
 
 
Scanning electron microscopy 
SEM images of the PLGA nanoparticles (G50, G25 and G15) 
loaded with Aripiprazole were shown in Figure 2. The particles had 
spherical in shape and smooth surface with diameters of 10 øm, 
and narrow size distributions which could be related to the data 
measured by size analyser.  
 
 
 
Figure 2. Scanning electron micrographs of Aripiprazole loaded PLGA nanoparticles  G50, G25 and G15 
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In-vitro release studies 
In vitro release kinetics of Aripiprazole from G50, G25 and G15 
PLGA nanoparticles are shown in Figure 3. The drug release 
process over a long period of time is expected to be influenced by 
the polymer L:G ratio since the process is controlled by 
degradation rate of polymer, which is affected by polymer 
hydrophobicity. Strong L:G dependence of release profile has been 
reported [17] for a hydrophobic drug (paclitaxel) incorporated in 
PLGA nanoparticles. In this case the drug release mechanism was 
a combination of drug diffusion and polymer degradation.                                     
 
Figure 3. In vitro release kinetics of Aripiprazole from G50, G25 
and G15 PLGA nanoparticles 
In contrast, the nanoparticles studied here release the Aripiprazole 
without a detectable change in effective diameter. Thus, the 
mechanism governing release from these nanoparticles is 
predominantly drug diffusion. During the drug release process, the 
drug diffuses through the hydrated polymer matrix into the aqueous 
phase. The process of hydration relaxes the polymer chains and 
enhances the diffusion of drug molecules. The rate of water uptake 
(hydration) of polymer particles increases with the hydrophilicity of 
polymer. Hence the initial burst is higher for more hydrophilic PLGA 
50:50 particles than less hydrophilic PLGA 85:15 particles. The 
induction period is also effected by polymer hydrophobicity. 
Decreasing the hydrophobicity increases the rate at which the 
diffusion of the release medium moves from the surface to the 
core, which makes more drug available for diffusion in a less time 
and thus reduces the induction period. 
Mathematical modeling of drug release  
The drug release from polymeric micro/nano-particulate systems is 
usually considered as a combination of Fickian (diffusion) and non-
Fickian movement of drug molecules through polymer chains [18]. 
Ritger and Peppas [19, 20] gave the semi-empirical equation to 
describe the release of solute when the prevailing mechanism is a 
combination of Fickian and non-Fickian mechanisms. 
Mt/M? = Ktn + ?   (1) 
Where Mt is the drug released at time t, M? is the quantity of the 
drug released at infinite time, K is constant, n is an exponent, and ? 
represents the drug released at zero time and accounts for the 
initial burst [21]. The value of n is related to both the geometrical 
shape of the formulation and the release mechanism. For drug 
release from spherical particles, the value of n is equal to 0.43 for 
pure Fickian and 0.85 for pure non-Fickian mechanisms. 
We fit our experimental release data to theoretical release profiles 
given by equation 1 and determine the value of the exponent n. 
The values of different parameters corresponding to the best-fit 
lines are given below.  
Mt/M? = 0.053 t0.433 +46  (2) 
Mt/M? = 0.078 t0.438 +23  (3) 
Mt/M? = 0.112 t0.435 + 4  (4) 
The value of n is  Ӌ0.43 for various particle sizes indicating that the 
drug release is diffusion controlled. The experimental and 
theoretical profiles for PLGA 50:50 particles start deviating at  Ӌ10 
days, after which the release becomes slower than predicted by 
the diffusion equation. This deviation of release profiles starts at a 
much later time for PLGA 85:15 particles. This deviation suggests 
that the release mechanism is diffusion controlled for the initial few 
days, after which the role of polymer degradation becomes 
important in PLGA 50:50 particles. The polymer degradation is 
faster for PLGA particles. The polymer degradation is faster for 
PLGA 50:50 particles than for PLGA 85:15 particles and hence the 
deviation from experimental profiles is observed much earlier for 
PLGA 50:50 particles. 
Conclusions 
Aripiprazole loaded PLGA nanoparticles were produced by 
emulsion/solvent evaporation method and tested for their in-vitro 
release behavior. The three most important properties affecting the 
release behavior were identified as: polymer hydrophobicity (L:G 
ratio), drug content and particle size. The mechanism of drug 
release was confirmed to be diffusion controlled by the application 
of mathematical models and the corresponding drug diffusivities 
were established to be a function of both polymer hydrophobicity 
and particle size. Hence the release profile from Aripiprazole 
loaded PLGA nanoparticles can be tailored to achieve desired 
objectives by selective manipulation of particle properties.  
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